Knoll Capital Management’s Cardiol Therapeutics CRDL Stock Holding History

Knoll Capital Management’s Portfolio CRDL Stock Details CRDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-100,000	Closed	-$135K	–	38
2026 Q1	$135K	Hold	100,000	–	–	0.07%	34
2025 Q4	$95.3K	Hold	100,000	–	–	0.04%	32
2025 Q3	$107K	Hold	100,000	–	–	0.06%	37
2025 Q2	$136K	Hold	100,000	–	–	0.1%	37
2025 Q1	$96.9K	Hold	100,000	–	–	0.06%	36
2024 Q4	$128K	Hold	100,000	–	–	0.08%	32
2024 Q3	$198K	Hold	100,000	–	–	0.09%	34
2024 Q2	$202K	Buy	+100,000	New	+$212K	0.14%	34

Other funds holding CRDL

MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Integrity Alliance Urbandale, Iowa $3.2B AUM 23.28% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Knoll Capital Management's CRDL Position: Q2 2026 in Review

Knoll Capital Management sold out of Cardiol Therapeutics (CRDL) in Q2 2026, closing a stake of 100,000 shares — an estimated $135K sold.

Knoll Capital Management first reported a position in CRDL in Q2 2024 and held it in 8 quarters. The position peaked at $202K in Q2 2024. 52 funds tracked by Wall St. Rank hold CRDL as of Q2 2026.

Knoll Capital Management reported no remaining Cardiol Therapeutics position as of Q2 2026 after selling out during the quarter.
Knoll Capital Management sold 100,000 Cardiol Therapeutics shares in Q2 2026, an estimated $135K.
Knoll Capital Management first reported a position in Cardiol Therapeutics in Q2 2024 and held it in 8 quarters.
Knoll Capital Management's Cardiol Therapeutics position peaked at $202K in Q2 2024.
52 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q2 2026.

Based on Knoll Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.